GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuren Pharmaceuticals Ltd (OTCPK:NURPF) » Definitions » EBITDA Margin %

NURPF (Neuren Pharmaceuticals) EBITDA Margin % : 16.71% (As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Neuren Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Neuren Pharmaceuticals's EBITDA for the six months ended in Jun. 2024 was $4.1 Mil. Neuren Pharmaceuticals's Revenue for the six months ended in Jun. 2024 was $24.3 Mil. Therefore, Neuren Pharmaceuticals's EBITDA margin for the quarter that ended in Jun. 2024 was 16.71%.


Neuren Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for Neuren Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuren Pharmaceuticals EBITDA Margin % Chart

Neuren Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -10.97 85.90

Neuren Pharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 76.51 89.27 16.71

Competitive Comparison of Neuren Pharmaceuticals's EBITDA Margin %

For the Biotechnology subindustry, Neuren Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuren Pharmaceuticals's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Neuren Pharmaceuticals's EBITDA Margin % falls into.



Neuren Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Neuren Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=135.734/158.011
=85.90 %

Neuren Pharmaceuticals's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=4.064/24.327
=16.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuren Pharmaceuticals  (OTCPK:NURPF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Neuren Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Neuren Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuren Pharmaceuticals Business Description

Traded in Other Exchanges
Address
697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.